Dose-Finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.
This study has been completed.
Information provided by:
First received: September 11, 2005
Last updated: NA
Last verified: September 2005
History: No changes posted
The objective of the study is to find the optimal dose for the smallpox candidate vaccine IMVAMUNE (MVA-BN). For this purpose the study compares IMVAMUNE (MVA-BN) administered at three different dose levels.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Prevention
|Official Title:||Phase II, Double-Blind, Randomised, Dose-Finding Study to Evaluate the Immunogenicity of Three Different Doses of MVA-BN Smallpox Vaccine in 18-30 Year Old Smallpox naïve Healthy Subjects|
Resource links provided by NLM:
U.S. FDA Resources
Further study details as provided by Bavarian Nordic:
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00189956
|Swiss Pharma Contract|
|Basel, Switzerland, 4123|
Sponsors and Collaborators
|Principal Investigator:||Rolf Pokorny, M.D.||Swiss Pharma|